SCHEMBL6337646

SCHEMBL6337646

CCC(CC)Oc1ccc(Oc2ccc(CC(=O)Nc3ccccc3C(=O)O)cn2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
PKM P14618 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HCAR2 Q8TDS4 5/20 0.44
KDM4E B2RXH2 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GAA P10253 1/20 0.42
POLB P06746 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.42
LMNA P02545 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2C9 P11712 1/20 0.41
KDM6B O15054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8039697 0.88 ALDH1A1 (0.55) ALDH1A1PKMSMN1; SMN2HCAR2KDM4E
SCHEMBL6340688 0.86 ALDH1A1 (0.42) ALDH1A1PKMSMN1; SMN2HCAR2KDM4E
SCHEMBL6582641 0.80 HCAR2 (0.62) ALDH1A1PKMSMN1; SMN2HCAR2KDM4E
SCHEMBL6340616 0.80 MEN1 (0.54) ALDH1A1PKMSMN1; SMN2HCAR2KDM4E
SCHEMBL6341406 0.79 KMT2A (0.51) ALDH1A1SMN1; SMN2KDM4EL3MBTL1KMT2A
SCHEMBL8037875 0.79 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2KDM4EL3MBTL1GAA
SCHEMBL6346488 0.79 CTSV (0.46) ALDH1A1PKMSMN1; SMN2HCAR2KDM4E
SCHEMBL6339661 0.78 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2KDM4EGAAPOLB
SCHEMBL6348820 0.78 KMT2A (0.43) ALDH1A1SMN1; SMN2KDM4EL3MBTL1POLB
SCHEMBL8027743 0.77 ALDH1A1 (0.56) ALDH1A1PKMSMN1; SMN2HCAR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 ALDH1A1 250/4885PKM 4728/4885SMN1; SMN2 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.